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Background: The role of dopamine agonists in the treatment of Cushing’s disease (CD) has been
previously debated.
Aim:Theaimof this studywas toevaluate theeffectivenessof short-term (3months) and long-term
(12–24 months) treatment with cabergoline in patients with CD.
Patients and Methods: 20 patients with CD unsuccessfully treated by surgery entered the study.
Cabergolinewas administered at an initial dose of 1mg/wk, with amonthly increase of 1mg, until
urinary cortisol levelsnormalizedor themaximaldoseof7mg/wkwasachieved.The responsiveness
to treatment was evaluated according to changes in urinary cortisol excretion. A decrease greater
than 25% was considered as a partial response, whereas complete normalization was considered
as a full response at short-term evaluation; persistence of normal cortisol excretion was the only
criterion to evaluate the response at long-term evaluation.
Results:After short-term treatment, 15 (75%) patients were responsive to cabergoline treatment.
Among these, normalizationof cortisol excretionwasmaintained in 10,whereas treatment escape
was observed in five patients after 6–18 months. Among the 10 long-term responsive patients,
eight were followed for 24months, whereas the remaining twowere followed for 12–18months,
due to cabergoline withdrawal for intolerance. A sustained control of cortisol secretion for 24
month cabergoline treatment at themaximal dose ranging from 1-7mg/wk (median: 3.5) without
significant side effects, was obtained in eight of 20 (40%) patients.
Conclusions: The results of this study demonstrated that cabergoline treatment is effective in
controlling cortisol secretion for at least 1–2 yr in more than one third of a limited population of
patients with CD. If this evidence is confirmed by additional studies, this agent may be considered
as a useful treatment option in patients with CD who are unsuccessfully treated by neurosurgery.
(J Clin Endocrinol Metab 94: 223–230, 2009)
Cushing’s disease (CD) is themost common formofCushing’ssyndrome, caused by a corticotroph pituitary tumor, and
often complicated by hypertension and impaired glucose toler-
ance and associated with increased morbidity and mortality for
cardiovascular diseases (1–3). The first-line treatment of CD is
surgery, with the objective of removing the pituitary tumor, al-
though it is effective in inducing immediate disease remission in
around 70% and late disease remission in around 50% of pa-
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tients (4, 5). Pituitary irradiationandbilateral adrenalectomyare
the alternative therapeutic approaches to CD, but they can be
associated with significant complications. Pharmacotherapy is
not currently used in the treatment of CD, except for adrenal
blocking drugs, used as transient palliative treatment before de-
finitive cure (4, 5).However, althoughnodrughasdemonstrated
a sufficient effectiveness in controlling cortisol secretion and in-
ducing tumor shrinkage in CD, the dopamine agonist bro-
mocriptine was reported to inhibit cortisol secretion in a limited
group of patients after short-term therapy, and in sporadic pa-
tients after long-term treatment (6–8). Recently, a preliminary
report of this study described that a short-term treatment with
the potent dopamine agonist cabergoline controlled cortisol se-
cretion in six of 10 (60%) patients with CD, suggesting that
cabergoline could be more efficacious than bromocriptine in the
management of this disease (9).
The aim of the current study was to evaluate the effectiveness
of short-term and long-term treatment with cabergoline on
ACTH and cortisol secretion, tumor size, and systemic compli-
cations in patients with CD who are unsuccessfully treated by
surgery.
Patients and Methods
Patients
Twenty patients (15 females, five males, 24–60 yr) with persistent
CD after unsuccessful surgery entered the study after their informed
consent had been obtained. The diagnosis of CD was mainly based on:
1) elevated daily urinary cortisol excretion (two or more times the upper
limit of normal range) with inappropriately high plasma ACTH concen-
trations (20 pg/ml); 2) failure of serum cortisol suppression (18 g/
liter) after low-dose but greater than 50% decrease after high-dose oral
dexamethasone suppression test; and 3) evidence of a pituitary tumor at
magnetic resonance imaging (MRI) of the pituitary gland or at the bi-
lateral inferior petrosal sinus sampling (1, 2). The diagnosis of the per-
sistence of CD after surgery was based on: 1) documentation of a cor-
ticotroph pituitary lesion (adenoma or hyperplasia) at the histological
and immunohistochemical study (19 patients), or the persistence of the
presurgical clinical syndrome, hormonal pattern, and pituitary tumor (1
patient); and 2) elevated daily urinary cortisol excretion (1, 2). The in-
clusion criteria for the study included: 1) persistence of CD after surgery
and 2) elevated urinary cortisol excretion 1.5 or more the upper limit of
normal range. At the beginning of the study all patients included in the
study hadbaseline urinary cortisol levelsmore than2.0 times higher than
the upper limit of the normal range. Mild hyperprolactinemia was
present in nine of 20 patients (45%). Pituitary tumor was detectable in
15 of the 20 patients. Hypertension was present in 13 of 20 (45%)
patients, and was treated by a different combination of antihypertensive
drugs, whereas diabetes mellitus was present in six patients, which were
under dietary treatment without or with the association of metformin.
The patients included in the study had been operated 0.5–5 years before
the study: those operatedmore than six months before, had been treated
with ketoconazole since 3 months before the study. Patients’ profile at
study entry is shown in Table 1.
Study design
The study design was in accordance with the Helsinki Doctrine on
HumanExperimentation, and it was approved by the local Ethical Com-
mittee. The study protocol included the evaluation of short-term (3
months) and long-term (12–24 months) effectiveness of cabergoline
treatment on clinical, biochemical, and radiological features, focusingon
the complications of the disease. Cabergoline (Dostinex; Pharmacia-
Pfizer, New York, NY) was administered at the initial dose of 1 mg/wk
(0.5mg twice aweek), progressively increased by 1mg everymonth until
normalization of urinary cortisol levels or a maximal dose of 7 mg/wk
(1 mg/d) had been reached. The study was performed in a single center
(Federico II University of Naples).
Responsiveness to treatment
After short-term treatment, patientswhoachieved anormalizationof
urinary cortisol levels were considered full responders, whereas those
who achieved a 25%ormore decrease without normalization of urinary
cortisol levelswere considered partial responders. Patientswho achieved
less than a 25% decrease of urinary cortisol levels were considered re-
sistant. After long-term treatment, the presence of urinary cortisol levels
within the normal range was the only criterion to evaluate the respon-
siveness to treatment. A re-increase of urinary cortisol levels at least to
the baseline levels after their normalization was considered an escape
from treatment. The responsiveness to short-term treatment with caber-
goline in terms of urinary cortisol changes in 10 of the 20 patients of the
study (nos. 1–10 in Table 1) has been already described in a previous
report (9).
Effectiveness and safety of treatment
The clinical study included the evaluation of body mass index, as
index of general obesity and waist to hip ratio, as index and visceral
obesity, systolic and diastolic blood pressure, and heart rate. The bio-
chemical study included the evaluation of serum glucose and insulin
levels, as well as the homeostasis model of assessment-insulin resistance
(HOMA-IR) and homeostasis model of assessment--cell function
(HOMA-B) indexes, markers of insulin resistance and insulin secretion,
respectively, together with the evaluation of serum prolactin (PRL),
plasma ACTH, serum and urinary cortisol levels, for which the mean of
three urinary collectionswas considered. The prevalence of hypertension
was evaluated by the measurement of blood pressure, considering a di-
agnosis of hypertension when systolic and diastolic blood pressure were
above 140 and above 90mmHg, respectively. The prevalence of glucose
intolerance was evaluated on the basis of glucose levels at fasting and/or
after a oral glucose tolerance test. Diabetesmellitus was diagnosedwhen
fasting serumglucose levelsweremore than126mg/dl in twoconsecutive
determinationsormore than200mg/d2hafter theglucose load,whereas
an impairment of glucose tolerance was diagnosed when fasting serum
glucose levels were between 100 and 126 mg/dl, and between 140 and
200 mg/dl 2 h after the glucose load. In patients under treatment with
antihypertensive or antidiabetics drugs, these were withdrawn for 1 wk
to evaluate the presence of hypertension and/or glucose intolerance. Se-
rum insulin was measured by solid-phase, two-site sequential chemilu-
minescent immunometric assay. The cross-reactivity of insulin with pro-
insulin was 8.5%. Plasma ACTH as well as serum PRL were measured
by a solid-phase two-site sequential chemiluminescent immunometric
assay, whereas serum and urinary cortisol were measured by a solid-
phase competitive chemiluminescent enzyme immunoassay. The normal
range for urinary cortisol levels was 35–135 g/d, obtained measuring
urinary cortisol levels on a large number of normal subjects of different
age. The radiological study included the evaluation of the tumor volume
by MRI, performed on clinical 1.5-T scanners, before and after gado-
linium administration. A more than 25% shrinkage was considered sig-
nificant. Tumor volume was evaluated only in the 15 patients with de-
tectable tumor at MRI during the study. The presence of cardiac valve
disease was investigated by an echocardiography performed at study
entry and every 6 months during the entire period of treatment.
Statistical analysis
The statistical analysis was performed by SPSS for Windows (SPSS,
Inc., Chicago, IL). The comparison between baseline and posttreatment
parameters was performed by the Wilcoxon or Friedman test. The as-
sociation studywasperformedby the2 test correctedby the Fisher exact
test, whereas the correlation study was performed with regression anal-
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ysis calculating the Pearson’s coefficient. Data are expressed as mean SE.
Significance was set at 5%.
Results
Responsiveness to treatment with cabergoline
At short-term treatment, 15 (75%) patients were responsive
[eight (40%) partial and seven (35%) full responders], whereas
five (25%) were resistant. Cabergoline was withdrawn in all
resistant patients, except in one,who continued treatment for 12
months.Among the15 responsivepatients, sixof the eight (75%)
partial responders normalized cortisol levels after 6–12 month
treatmentwith increasing cabergoline dose.However, twoof the
seven (28.6%) full responders and three of the eight (37.5%)
partial responders experienced a treatment escape after 12–18
month treatment, and stopped treatment. At the 12-month fol-
low-up, 10 (50%) patients were persistently controlled at the
median cabergoline dose of 6 mg/wk (1–7 mg/wk). Cabergo-
line was discontinued during the second year of follow-up in
two (10%) patients who did not tolerate the treatment be-
cause of severe asthenia associated with hypotension. At the
24-month follow-up, eight (40%) patients were persistently
controlled at a median cabergoline dose of 3.5 mg/wk (1–7
mg/wk) (Figs. 1 and 2). In these patients, all multiple urinary
cortisol levels were within the normal range, or very close to
the upper limit of the normal range. A flowchart explaining the
disposition of the different patients during the short-termand long-
term study and the corresponding outcome of the treatment is
shown in Fig. 3. The presence of hyperprolactinemia was signifi-
cantlyassociatedwiththeresponsiveness toshort-term(25.455;
P 0.038), but not long-term (2 5.051;P 0.070), treatment.
Effectiveness of treatment with cabergoline
Short-term treatment (Table 2)
The clinical picture improved in the majority of responsive
patients, whereas it mildly improved, remained stable, or
mildly worsened in resistant patients. Despite a mild increase
of body mass index, waist to hip ratio significantly decreased,
as well as blood pressure, serum glucose and insulin, HOMA-
IR, and tumor volume. Systolic and diastolic blood pressure
significantly decreased in resistant patients as well, whereas
HOMA-B did not change both in responsive and resistance
patients. PRL levels were lower than the normal range in all
patients.
Long-term treatment
Responsive patients (Table 3). The clinical picture further im-
proved during treatment. Body mass index slightly increased
during the first 3–6 months, but significantly decreased there-
after, whereas waist to hip ratio progressively decreased. The
prevalence of overweight or obesity decreased from 87.5% at
baseline to 62.5% at the 24-month treatment. The distribution
of fat mass was modified from an abdominal to a generalized
pattern in the majority of patients. Muscle mass and strength as
well as skin features slightly or significantly improved in the
majority of patients. Systolic and diastolic blood pressure values
significantly decreased, becoming stable after 6–12month treat-
ment. The prevalence of hypertension decreased from 50% at
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FIG. 1. Urinary cortisol levels during the entire period of treatment in all 20 patients treated with cabergoline. The patients long-term response to cabergoline
treatment are shown with black lines, those with early response and late escape are shown with purple lines, and those nonresponders to the treatment are
shown with red lines. The shaded area indicates the normal range of urinary cortisol levels (35–135 g/d). Urinary cortisol levels represent the mean of three
different urine collections performed on three different nonconsecutive days of the same week.
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baseline to 0% after 24 month treatment, when specific antihy-
pertensive treatment (an angiotensin converting enzyme inhibi-
tor plus a diuretic agent in two, an angiotensin receptor blocker
plusadiuretic agent inone, andacalciumantagonist inonepatient)
was completely withdrawn. Fasting serum glucose and insulin lev-
els, as well as HOMA-IR, but not HOMA-B, significantly de-
creased; the prevalence of diabetes mellitus and impairment of glu-
cose tolerance changed from 25 and 37.5% at baseline to 10 and
20%after 24month treatment, respectively.Metformin treatment
was withdrawn in one of the two patients with diabetes, who be-
came controlled by only a dietary treatment. PRL levelswere lower
than normal range in all patients. A decrease of tumor volumewas
observedduring the entire periodof treatment. Inparticular, tumor
shrinkage was observed in four (50%), whereas a stable tumor
volume was found in the remaining responsive patients.
Escaped patients (Table 4)
The clinical picture slightly worsened with the treatment es-
cape.However, at the last follow-up, systolic and diastolic blood
pressure, andHOMA-IRwere still decreased comparedwith the
baseline. No change of tumor volume was found after the treat-
ment escape, whereas a slight increase was observed in the only
resistant patient who continued treatment for 12 months.
Tolerance
No significant side effect was documented except hypoten-
sion (80/50 mm Hg) associated with severe asthenia in two pa-
tients, who stopped treatment after 12 and 18 months of treat-
ment, respectively. A transient moderate asthenia was registered
in four patients, whereas a transient mild dizziness with nausea
was reported by another patient during the first period of treat-
ment. These latter side effects did not require treatment with-
drawal. No patient experienced any deterioration of cardiovas-
cular function, or any significant symptom or sign related to
cardiac disease; in particular, no development of cardiac valve
insufficiency or worsening of previously diagnosed valve insuf-
ficiency was documented in the patients of the study, except in
one who had a mild tricuspid regurgitation at baseline and a
moderate tricuspid regurgitation with normal pulmonary pres-
sure after 2 yr treatment.
Discussion
The current study represents the extension of a previously re-
ported preliminary study (9). Indeed, this is the first study eval-
uating the chronic effectiveness of cabergoline treatment in CD.
The results of the study demonstrated that a 24-month treatment
with cabergoline, at a variable dose between 1 and 7 mg/wk,
induces or maintains control of cortisol secretion in 40% and
induces tumor shrinkage in 20% of a group of 20 patients with
CD, improving hypertension and glucose intolerance in the ma-
jority of patients, regardless of the normalization of cortisol
secretion.
Presently, a real medical treatment for CD, acting at the level
of the pituitary tumor, does not exist. Indeed, although several
neuromodulatory drugs were used, no single agent has ever been
demonstrated to be effective sufficiently to achieve a widespread
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FIG. 2. Changes in urinary cortisol levels after short-term (top) and long-term
(bottom) treatment with cabergoline. The eight patients with a 24-month follow-
up are shown with a continuous arrow, whereas the two patients with 12–18
months of follow-up are shown with an interrupted arrow. The number on each
arrow indicates the maximal dose of cabergoline expressed in mg per week
administered to the patients during short-term and long-term treatment. The
gray area indicates the upper limit of normal of the urinary cortisol levels (135
g/d). Urinary cortisol levels represent the mean of three different urine
collections performed on three different nonconsecutive days of the same week.
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Partial
response
(8)
Short-term
study
Response
(6)
Escape
(5)
Response
(4)
Long-term 
study
(3) (2)
Cabergoline withdrawal 
and study drop-out
Intolerance
(2)
Short-term efficacy
(75%)
Long-term efficacy
(40%)
Response
and
Tolerance
(8)
FIG. 3. Flowchart illustrating the disposition of the different patients during short-
term and long-term study, and the corresponding outcome of the treatment.
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clinical use in the management of CD (4, 5). However, the do-
pamine agonist bromocriptine was reported to induce a signif-
icant inhibition or normalization of cortisol secretion in about
40% of patients after short-term treatment (5, 6, 10, 11), al-
though controversial and variable results were obtained by dif-
ferent studies on short-term treatment (5), and normalization of
cortisol secretion was rarely maintained and tumor shrinkage
sporadically detected after long-term treatment (5, 7, 8). This
evidence suggested that only a subset of patients with CD was
able to respond to chronic treatmentwith bromocriptine.On the
other hand, the potent dopamine agonist cabergoline induced a
normalization of ACTH and/or cortisol secretion and/or a sig-
nificant tumor shrinkage in two ACTH-secreting pituitary tu-
mors associatedwithNelson’s syndrome (12, 13), a silentACTH
(14), an aberrant ACTH-secreting (15), and amixed ACTH and
PRL-secreting (16) pituitary tumors.Moreover, in a preliminary
report of this study on the first 10 patients withCD, a short-term
cabergoline treatment induced a significant inhibition of cortisol
secretion in six (60%) and normalization in four (40%) patients,
suggesting a higher effectiveness of cabergoline than bromocrip-
tine in the treatment of CD (9). However, no study has ever
evaluated the effectiveness of long-term treatment with caber-
goline in patients with CD.
The results of the current study confirmed that a short-term
treatment with cabergoline is able to induce an inhibition of
cortisol secretion in 15 (75%), and normalization in seven
(35%), out of 20 patients with CD. In addition, they demon-
strated a successful effectiveness of cabergoline after long-term
treatment as well. Among the patients with an initial respon-
siveness, five experienced a treatment escape and two drug in-
tolerance. Therefore, half of the patients with a short-term re-
sponsiveness continued to respond with stable normal cortisol
TABLE 2. Clinical, biochemical, and radiological features of the 20 patients with CD treated with cabergoline at baseline and
after short-term treatment
Parameter
Responsive patients (n  15)
P value
Resistant patients (n  5)
P
valueBaseline
3-month
treatment Baseline
3-month
treatment
Body mass index (kg/m2) 27.5  0.8 28.0  0.8 0.115 27.7  1.3 28.4  1.3 0.066
Waist to hip ratio 1.10  0.04 1.08  0.04 0.001 1.05  0.06 1.07  0.06 0.221
Systolic blood pressure (mm Hg) 146.0  3.6 135.7  2.9 0.001 149.0  5.8 138.0  3.7 0.041
Diastolic blood pressure (mm Hg) 94.0  2.4 87.3  2.2 0.002 95.0  4.2 88.0  3.7 0.038
Heart rate (beats/min) 69.5  1.8 74.1  2.3 0.014 63.2  1.3 65.0  0.5 0.109
Fasting serum glucose (mg/dl) 129.3  5.6 121.8  4.0 0.004 124.2  7.7 116.2  3.1 0.136
Fasting serum insulin (U/ml) 11.0  1.2 10.1  1.2 0.001 14.4  1.2 13.7  1.1 0.104
HOMA-IR 3.6  0.5 3.1  0.4 0.002 4.4  0.5 4.0  0.3 0.138
HOMA-B (%) 65.0  7.2 65.4  7.4 0.865 92.0  17.1 94.0  9.4 0.500
Plasma ACTH (pg/ml) 64.9  3.3 56.3  3.1 0.002 78.0  10.3 78.6  9.6 0.893
Serum cortisol (g/liter) 239.3  13.9 177.1  13.4 0.001 288.8  21.1 276.8  14.5 0.686
Urinary cortisol (g/d) 561.9  52.5 192.0  29.1 0.001 674.4  100.5 642.2  70.6 0.345
Tumor volume (mm3) 246.5  40.9 230.7  41.5 0.047 565.3  391.2 573.1  394.3 0.109
Normal ranges for: fasting serum glucose, 60–110 mg/dl; serum insulin, 1–20 U/ml; plasma ACTH, 10–130 pg/ml; serum cortisol, 50–200 g/liter; urinary cortisol,
35–135 g/d; and serum PRL, 0–25 g/liter for females and 0–15 g/liter for males. Urinary cortisol levels represent the mean of three different urine collections.
TABLE 3. Clinical, biochemical, and radiological features of patients with CD long-term responsive to cabergoline treatment
Parameter
Baseline
(10 patients)
12-month treatment
(10 patients)
24-month treatment
(8 patients) P value
Body mass index (kg/m2) 28.2  0.9 28.0  0.8 27.1  0.7a 0.011
Waist to hip ratio 1.12  0.06 1.03  0.06b 1.01  0.06a 0.002
Systolic blood pressure (mm Hg) 141.5  4.4 118.0  5.1a 123.1  4.4a 0.015
Diastolic blood pressure (mm Hg) 91.0  2.5 75.0  3.8b 80.0  3.4a 0.002
Heart rate (beats/min) 71.5  2.3 79.7  2.2a 76.9  2.1 0.368
Fasting serum glucose (mg/dl) 128.2  8.1 115.0  3.2 106.0  5.2a 0.002
Fasting serum insulin (U/ml) 10.9  1.5 8.4  1.0b 7.2  1.0a 0.002
HOMA-IR 3.47  0.66 2.37  0.29b 1.88  0.29a 0.001
HOMA-B (%) 66.6  9.2 61.0  8.7 67.8  11.3 0.607
Plasma ACTH (pg/ml) 62.4  6.1 45.4  3.6b 35.6  3.2a 0.002
Serum cortisol (g/liter) 236.2  17.6 160.2  6.0b 144.6  10.5a 0.002
Urinary cortisol (g/d) 558.1  69.1 118.5  12.2b 115.4  7.8a 0.002
Tumor volume (mm3) 224.3  31.9 158.1  46.2a 133.7  56.7a 0.084
Normal ranges for: fasting serum glucose, 60–110 mg/dl; serum insulin, 1–20 U/ml; plasma ACTH, 10–130 pg/ml; serum cortisol, 50–200 g/liter; urinary cortisol,
35–135 g/d; and serum PRL, 0–25 g/liter for females and 0–15 g/liter for males. Urinary cortisol levels represent the mean of three different urine collection.
P values indicate the global significance.
a P  0.05 compared with baseline.
b P  0.01 compared with baseline.
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levels for a period as long as two years. It has to be pointed out
that although five patients were completely resistant and seven
patients withdrew cabergoline for treatment escape or intoler-
ance, sixof eightpatients partially responsive to short-term treat-
ment became fully responsive after increasing the cabergoline
dose, and three of them showed a persistent normalization of
cortisol secretion during long-term treatment, suggesting that
the cabergoline dose and the period of treatment necessary to
normalize cortisol secretion were extremely variable for each
patient with CD. Considering the entire population of 20 pa-
tients, cabergolinewas able to stably control cortisol secretion in
50%patients after 1 yr and 40%of patients after 2 yr treatment.
It is noteworthy that at the diagnosis, 45%of patients had amild
hyperprolactinemia, which were significantly associated with
short-term but not long-term responsiveness to cabergoline
treatment. This evidence seems to suggest that the presence of
hyperprolactinemia could be considered amarker of responsive-
ness to initial but not chronic cabergoline treatment.
An important finding of the current study was the demon-
stration that cabergoline treatment improved hypertension and
glucose intolerance in patients with CD. In fact, blood pressure
and theprevalenceof hypertensionalreadydecreasedafter short-
term and nearly normalized in the majority of patients during
long-term treatment. On the other hand, glucose and insulin
levels aswell as insulin resistance, and the prevalence of impaired
glucose tolerance or diabetes mellitus decreased during long-
term treatment. Moreover, the improvement of hypertension
andglucose intolerance in patientswhowere resistant or escaped
from treatment suggest that cabergoline might directly and pos-
itively influence blood pressure and glucose tolerance indepen-
dently of the change in cortisol secretion. The direct effect of
dopamine agonists on hypertension is largely documented and
justified by the expression of dopamine receptors in the vascular
system, where they mediate a relaxing effect, with a consequent
reduction of peripheral resistance (17). The direct effect of do-
pamine agonists on glucose tolerance is supported by the evi-
dence that bromocriptine is able to improve glucose homeostasis
in patientswith diabetesmellitus, probably due to a potentiation
of insulin-mediated suppressionofhepatic glucoseproductionor
stimulation of splanchnic glucose uptake (18). The results of this
study concur with these hypotheses and suggest that even when
no effect on cortisol secretion was found, cabergoline may have
a consistent impact on blood pressure and glucose intolerance.
Another essential point of this study was the demonstration
that cabergoline did not inducemajor side effects in patientswith
CD. Hypotension associated with severe asthenia was only
found in two patients, probably because of the direct effect of
cabergoline on the vascular system. It is noteworthy that no
significant cardiac valve dysfunctionwas found in the patients of
the study, with the exception of a slight worsening of tricuspid
regurgitation inonepatient.This is a crucial point because caber-
goline treatment has been recently described to be associated
with an increased prevalence of cardiac valve insufficiency in
patients with Parkinson’s disease (19, 20). However, patients
with Parkinson’s disease are often elderly patients, and are
treated with a high dose of the drug for a long period of time.
Although patients with CD often require higher doses of caber-
goline than those with hyperprolactinemia, the doses are still
sensibly lower than those used by patients with Parkinson’s dis-
ease and theperiodof treatmentwasonly2years.This couldhelp
to explain the reason for the lack of cardiac valve disease in the
group of patients of this study with CD.
In conclusion, the current study demonstrated that cabergo-
line is effective in controlling cortisol secretion in more than one
third of a limited population of patients with CD during chronic
treatment, without major side effects. However, further studies
on a larger population of patients are mandatory to confirm the
results of the current study. If these data are confirmed, caber-
goline could be considered a useful tool in the management of
TABLE 4. Clinical, biochemical, and radiological features of patients with CD who experienced a treatment escape during the
long-term treatment with cabergoline
Parameter
Baseline
(5 patients)
6-month
treatment
(5 patients)
12-month
treatment
(5 patients)
18-month
treatment
(4 patients) P value
Body mass index (kg/m2) 26.1  1.6 26.6  1.5 25.9  1.3 26.6  1.6 0.546
Waist to hip ratio 1.07  0.05 1.00  0.06a 0.99  0.06a 1.08  0.07 0.027
Systolic blood pressure (mm Hg) 155.0  4.5 136.0  4.0a 139.0  3.7a 142.5  2.5 0.040
Diastolic blood pressure (mm Hg) 100.0  4.2 89.0  2.9a 91.0  3.7a 95.0  2.9 0.027
Heart rate (beats/min) 65.6  1.6 72.2  4.5 66.6  4.0 69.0  2.6 0.557
Fasting serum glucose (mg/dl) 131.4  5.6 119.0  4.4a 119.8  3.5a 125.3  1.3 0.209
Fasting serum insulin (U/ml) 11.4  2.3 10.4  2.4 9.6  2.1a 8.2  2.5 0.029
HOMA-IR 3.72  0.82 2.99  0.69a 2.84  0.65a 2.53  0.77 0.038
HOMA-B (%) 76.5  6.9 82.0  10.4 69.1  7.2 61.4  9.7 0.165
Plasma ACTH (pg/ml) 74.0  3.6 57.5  5.0a 59.0  13.1 76.0  10.4 0.022
Serum cortisol (g/liter) 245.4  25.0 157.4  11.0a 200.6  22.9 250.3  23.3 0.112
Urinary cortisol (g/d) 569.6  86.4 172.6  24.3a 377.8  68.1 623.0  49.5 0.019
Tumor volume (mm3) 277.8  92.0 268.7  85.5 0.465
Normal ranges for: fasting serum glucose, 60–110 mg/dl; serum insulin, 1–20 g/ml; plasma ACTH, 10–130 pg/ml; serum cortisol, 50–200 g/liter; urinary cortisol,
35–135 g/d; and serum PRL, 0–25 g/liter for females and 0–15 g/liter for males. Urinary cortisol levels represent the mean of three different urine collections.
P values indicate the global significance.
a P  0.05 compared with baseline.
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persistent and/or recurrent CD, andmay be proposed as the first
real causative medical treatment for CD.
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